Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Linde PLC — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Linde PLC trades at $496.13 (market cap $226.85B). The key difference: Linde PLC is far larger — about 79.3× Dyne Therapeutics Inc. Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Linde PLC for 89 Days on average.
| DYN | LIN | |
|---|---|---|
Market Cap | $2.86B | $226.85B |
Volume | 3,341,579 | 1,386,042 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $546.64 |
52-Week Low | $14.60 | $389.38 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $2.18B | $249.97B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Linde (LIN) trades at $487.35, up 0.75% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 20.43% net margins, and robust cash flow generation. Analyst consensus is overwhelmingly bullish with a $558.91 price target, representing 15% upside potential. Recent Q2 2026 results exceeded expectations with $4.50 EPS, driven by volume and pricing growth across key markets including electronics.
LIN offers quality exposure to industrial gases with AI chip contract potential, though elevated P/E of 31.75 requires sustained growth. Risks include margin pressure from higher CAPEX and sector-wide competition. The stock presents a compelling opportunity for investors seeking stable industrial exposure with growth catalysts, supported by strong institutional backing and consistent dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
